In Shanghai in June, the rain washed away the sweltering heat and brought coolness. Looking around, everything is full of vitality and lovely. In September last year, at the 2020 academic annual meeting of the CSCO Expert Committee on Integrative Traditional Chinese and Western Medicine, we held the launching ceremony of the "Expert Consensus on Integrative Traditional Chinese and Western Medicine for the Treatment of Bone Marrow Suppression Caused by Chemotherapy" in Qingdao, a city with green mountains, blue seas and red tiles and green trees. This year, in order to further improve the standardization level of my country's integrated traditional Chinese and Western medicine treatment of malignant tumors, reduce the incidence of tumor-related treatment toxicity, improve the quality of life of patients, and ensure medical safety, it is sponsored by the CSCO Expert Committee on Integrated Traditional Chinese and Western Medicine, and Hubei Mengyang Pharmaceutical Co., Ltd. Co., Ltd. assisted in the preparation of the "Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Antineoplastic Drugs", which lasted three months. At present, the first draft of the expert consensus has been completed, and an expert meeting was held simultaneously online and offline in Hongqiao Business District, Shanghai last weekend. Consensus review meeting.

A total of 20 experts, including Professor Li Pingping from Peking University Cancer Hospital, Chairman of CSCO Integrative Medicine Expert Committee, Professor Hua Haiqing, Vice Chairman, Secretary-General, leader and members of the consensus writing group, were invited to the meeting.

The meeting was presided over by Professor Zhang Yue, vice chairman of the conference and Jilin Provincial Cancer Hospital. The chairman of the conference, Professor Hua Haiqing of the Eastern Theater General Hospital of the People's Liberation Army, delivered a speech, and Ms. Zhou Huiying, deputy general manager of Mengyang Pharmaceutical, delivered a welcome speech.

In the academic exchange part, Jiang Ziyu, a member of the expert consensus writing group and deputy director of Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, brought everyone "Research Progress in the Treatment of Bone Marrow Suppression Caused by Antineoplastic Drugs with Traditional Chinese Medicine". It is described in three parts: an overview of bone marrow suppression, the etiology and pathogenesis of traditional Chinese medicine, and the progress of traditional Chinese medicine treatment. Among them, in the part of TCM treatment progress, the latest RCT research results of Shengbai Oral Liquid were shared: the incidence and degree of neutropenia and the incidence of thrombocytopenia after chemotherapy using Shengbai Oral Liquid for prevention and concurrent chemotherapy All have significant curative effect. Then, Yao Qinghua, member of the Standing Committee of the conference, leader of the expert consensus writing group, and director of Zhejiang Cancer Hospital, reported on the "consensus structure and introduction of each chapter".

Afterwards, the participating experts had a heated discussion on the details of each chapter of the consensus, and initially reached a certain consensus.

Myelosuppression is a common adverse reaction of anticancer drugs, which not only reduces the dose intensity and dose density of chemotherapy for cancer patients, but also brings adverse events such as infection and bleeding, which seriously affects the prognosis of patients. Traditional Chinese medicine is based on the theory of "preventing disease from disease" and advocates the principle of prevention first and combination of prevention and treatment, and attaches great importance to the overall concept and syndrome differentiation and treatment. It can not only prevent and treat bone marrow suppression, but also treat tumor itself and other complications. It can be seen that the writing of "Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Antineoplastic Drugs" can improve the standardization level of integrated traditional Chinese and Western medicine in the treatment of malignant tumors, reduce the incidence of tumor-related treatment toxicity, improve the quality of life of patients, and ensure medical safety. Significant.

Mengyang Pharmaceutical has been committed to digging out the treasures of traditional medicine in the motherland, developing the classic prescriptions of famous old Chinese medicine doctors and the active ingredients derived from natural medicines into new medicines to benefit more patients. Through the participation of this expert consensus project, we have made it clearer that it is necessary to carry out multi-center clinical research with large samples, in line with evidence-based medical norms and the scientific evaluation system of traditional Chinese medicine. Mengyang Pharmaceutical is also willing to actively participate in the research of traditional Chinese medicine In the work of scientific interpretation, together with experts who are struggling in the front line of clinical practice, we will jointly explore the theory and mechanism of traditional Chinese medicine prescriptions and contribute to the development of traditional Chinese medicine.